NCT01074138View on ClinicalTrials.gov

Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

June 30, 2012

Study Completion Date

October 31, 2012

Conditions
Bone-Metastatic, Castration-Resistant Prostate Cancer
Interventions
DRUG

KX2-391

KX2-391 will be administered as a 40 mg oral dosing solution, twice daily, for 6 28-day cycles.

Trial Locations (5)

21205

Johns Hopkins University, Baltimore

48201

Wayne State University-Karmanos Cancer Center, Detroit

53792

University of Wisconsin, Madison

60637

University of Chicago, Chicago

98109

University of Washington, Seattle

Sponsors

Lead Sponsor

Athenex, Inc.
All Listed Sponsors
lead

Athenex, Inc.

INDUSTRY